Beam Therapeutics (BEAM) Change in Acquisitions & Divestments (2019 - 2026)

Beam Therapeutics (BEAM) has reported Change in Acquisitions & Divestments for 8 consecutive years, with $181.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 16.51% year-over-year to $181.3 million; the TTM figure through Mar 2026 stood at $806.6 million (up 1006.04% YoY), while the FY2025 annual figure was $842.5 million, changed N/A from the prior year.
• Change in Acquisitions & Divestments eased to $181.3 million in Q1 2026 per BEAM's latest filing, from $836.7 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $836.7 million in Q4 2025 and bottomed at -$935.0 million in Q4 2023.
• Historically, Change in Acquisitions & Divestments has averaged $139.3 million across 5 years, with a median of $220.5 million in 2024.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments jumped 683.91% — and 2023, when it tumbled 359.64%.
• Beam Therapeutics' Change in Acquisitions & Divestments stood at $360.1 million in 2022, then slumped by 359.64% to -$935.0 million in 2023, then surged by 60.62% to -$368.1 million in 2024, then jumped by 327.29% to $836.7 million in 2025, then plunged by 78.33% to $181.3 million in 2026.
• Business Quant data shows BEAM's Change in Acquisitions & Divestments at $181.3 million in Q1 2026, $836.7 million in Q4 2025, and -$378.1 million in Q3 2025.